Open access · CC-BY
via OpenAlex
Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson’s Disease “Off” Episodes
Amnon A. Berger, Ariel A. Winnick, Jonathan J. Izygon, Binil Mathew Jacob, Jessica S. Kaye, Rachel J. Kaye, Elisa E. Neuchat, Adam Marc Kaye, E. Saunders Alpaugh, Elyse M. Cornett, Andrew Hogyu Han, Alan D. Kaye
Health Psychology Research · 2022 · ▲ 8 citations
Abstract
Parkinson's Disease (PD) is a common neurodegenerative disorder and the leading cause of disability. It causes significant morbidity and disability through a plethora of symptoms, including movement disorders, sleep disturbances, and cognitive and psychiatric symptoms. The traditional pathogenesis theory of PD involves the loss of dopaminergic neurons in the substantia nigra (SN). Classically, treatment is pursued with an assortment of medications that are directed at overcoming this deficiency with levodopa being central to most treatment plans. Patients taking levodopa tend to experience "off episodes" with decreasing medication levels, causing large fluctuations in their symptoms. These off episodes are disturbing and a source of morbidity for these patients. Opicapone is a novel, peripherally acting Catechol-O-methyl transferase (COMT) inhibitor that is used as adjunctive therapy to carbidopa/levodopa for treatment and prevention of "off episodes." It has been approved for use as an adjunct to levodopa since 2016 in Europe and has recently (April 2020) gained FDA approval for use in the USA. By inhibiting COMT, opicapone slows levodopa metabolism and increases its availability. Several clinical studies demonstrated significant improvement in treatment efficacy and reduction in duration of "off episodes." The main side effect demonstrated was dyskinesia, mostly with the 100mg dose, which is higher than the approved, effective dose of 50mg. Post-marketing surveillance and analysis are required to further elucidate its safety profile and contribute to patient selection. This paper reviews the seminal and latest evidence in the treatment of PD "off episodes" with the novel drug Opicapone, including efficacy, safety, and clinical indications.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.52965/001c.36074
- Canonical
- link ↗
- Fetched
- 2026-09-23 MST
Cite this
APA
Berger, A.A., Winnick, A.A., Izygon, J.J., Jacob, B.M., Kaye, J.S., Kaye, R.J., Neuchat, E.E., Kaye, A.M., Alpaugh, E.S., Cornett, E.M., Han, A.H., & Kaye, A.D. (2022). Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson’s Disease “Off” Episodes. <em>Health Psychology Research</em>. https://doi.org/10.52965/001c.36074
Vancouver
Berger AA, Winnick AA, Izygon JJ, Jacob BM, Kaye JS, Kaye RJ, et al. Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson’s Disease “Off” Episodes. Health Psychology Research. 2022. doi:10.52965/001c.36074.
BibTeX
@article{amnon2022Opicap,
title = {Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson’s Disease “Off” Episodes},
author = {Amnon A. Berger and Ariel A. Winnick and Jonathan J. Izygon and Binil Mathew Jacob and Jessica S. Kaye and Rachel J. Kaye and Elisa E. Neuchat and Adam Marc Kaye and E. Saunders Alpaugh and Elyse M. Cornett and Andrew Hogyu Han and Alan D. Kaye},
journal = {Health Psychology Research},
year = {2022},
doi = {10.52965/001c.36074},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Pharmacology 2019
Open access · CC-BY
Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update
Cells 2025
Open access · OA
Radiation-Induced Fibrosis (RIF) in Head and Neck Squamous Cell Carcinoma (HNSCC): A Review.
Cell Proliferation 2020
Open access · CC-BY
Advances in mesenchymal stem cell transplantation for the treatment of osteoporosis
Central Institute of Mental Health, Mannheim 2026
Open access · US-GOV
Electroconvulsive Therapy for Treatment of Alzheimer´s Disease
International Journal of Molecular Sciences 2021
Open access · CC-BY
Mesenchymal Stem Cell Transplantation for the Treatment of Age-Related Musculoskeletal Frailty
GeroScience 2024
Open access · CC-BY